HK Stock Market Move | IMMUNEONCO-B(01541) surges over 5% with Treg cell therapy receiving significant attention. The company is currently actively advancing the clinical development of TaiZe SuBai antibody.

IMMUNEONCO-B(01541) rose by more than 5%, reaching 5.22% as of the time of writing, with a price of HK$11.47 and a trading volume of HK$40.4765 million. On the news side, according to the official Weibo account of IMMUNEONCO-B, three scientists including Mary E. Brenko were awarded the 2025 Nobel Prize in Physiology or Medicine to honor their research in the field of peripheral immune tolerance mechanisms. This innovative research has identified an immune system suppressor switch, bringing revolutionary therapy to millions of autoimmune and cancer patients worldwide. Regulatory T cells (Treg cells) maintain immune tolerance through the Foxp3 transcription factor. Their dysfunction is closely related to autoimmune diseases, cancer, and the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is the "key effector molecule" for immune suppression by Treg cells. The discovery of Treg cells and their mechanisms of action provide a theoretical basis for developing a new generation of immune-regulating drugs. It is reported that the new generation CTLA-4 antibody developed by IMMUNEONCO-B, tazlestobart (IMM27M), exerts anti-tumor effects by eliminating Treg cells in the tumor microenvironment. IMMUNEONCO-B is currently actively promoting the clinical development of tazlestobart (IMM27M). Tazlestobart (IMM27M) is a new generation CTLA-4 antibody independently developed by IMMUNEONCO-B, which enhances ADCC activity through genetic engineering technology and can completely eliminate Treg cells in the tumor microenvironment. IMM27M is an innovative drug targeting Treg cells, the main mechanism of action is to target the specific molecule CTLA-4 on Treg cells, regulate their function or quantity, thus enhancing the immune response.